Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06855329 · ClinicalTrials.gov registry record

PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

A clinical trial of Interstitial Lung Disease and Progressive Pulmonary Fibrosis, sponsored by University of Massachusetts, Worcester.

Recruiting
Registry status
500
Enrollment target
13
Study locations

NCT06855329 is a study of Interstitial Lung Disease and Progressive Pulmonary Fibrosis that is actively recruiting participants, run by University of Massachusetts, Worcester. The registered enrollment target is 500 participants, below the 553-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (10% lower). The trial reports 13 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06855329, a study of Interstitial Lung Disease and Progressive Pulmonary Fibrosis, is actively recruiting participants, sponsored by University of Massachusetts, Worcester.

RECRUITING
Registry status
500 participants
Enrollment target
13
Study locations

Study Summary

This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over time, and 2) Determine whether multi-dimensional PPF prediction outperforms component approaches.

Conditions Studied

Interstitial Lung Disease Progressive Pulmonary Fibrosis

Study Locations (13)

Massachusetts

  • University of Massachusetts Chan Medical School - Worcester

Michigan

  • University of Michigan - Ann Arbor

Texas

  • University of Texas Southwestern - Dallas

Virginia

  • University of Virginia - Charlottesville

Washington

  • University of Washington - Seattle

New South Wales

  • Royal Prince Alfred Hospital - Camperdown

Queensland

  • Prince Charles Hospital - Brisbane

Victoria

  • Austin Health - Melbourne

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2025-05-01
Est. Completion 2029-12

Sponsor

University of Massachusetts, Worcester

240 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06855329

The ClinicalTrials.gov registry entry for NCT06855329 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 553-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (10% lower). The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Interstitial Lung Disease appearing as the primary indexed condition, and to 0 interventions.

NCT06855329 reports 13 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, Michigan, Texas.

Frequently Asked Questions

What is clinical trial NCT06855329 about?

NCT06855329 is a clinical study titled "PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis". This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis...

What is the current status of trial NCT06855329?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-05-01. Estimated completion is 2029-12.

What conditions does trial NCT06855329 study?

This clinical trial studies the following conditions: Interstitial Lung Disease, Progressive Pulmonary Fibrosis.

Who is sponsoring clinical trial NCT06855329?

This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06855329 being conducted?

This trial has 13 study locations across Massachusetts, Michigan, Texas, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Interstitial Lung Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Interstitial Lung Disease

All registered trials for this condition

Progressive Pulmonary Fibrosis

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.